Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular Risk

Open Forum Infect Dis. 2024 Sep 9;11(9):ofae502. doi: 10.1093/ofid/ofae502. eCollection 2024 Sep.

Abstract

The REPRIEVE trial suggests that primary cardiovascular disease (CVD) prevention could be considered among people with HIV at low CVD risk. We found cisgender women with low/moderate and high CVD risk are less likely to receive statins than cisgender men. Efforts are needed to guarantee equal access to statin-based CVD prevention.

Keywords: Cardiovascular prevention; gender disparities; people with HIV; prescription; statin.